Hypothesis

Enteric production of short-chain fatty acids (SCFAs) activates vagal afferents that tonically inhibit dopaminergic firing in the substantia nigra pars compacta, shifting the D1/D2 receptor activation ratio in the dorsal striatum toward D2 dominance. This gut‑to‑brain signal sets the basal ganglia’s homeostatic baseline, meaning that age‑related changes in striatal synchrony and habit formation arise secondarily to alterations in gut microbiota‑derived SCFA flux.

Mechanistic Basis

• SCFAs (acetate, propionate, butyrate) released by colonic microbes stimulate enteroendocrine cells to release peptide YY and serotonin, which activate vagal afferents via 5‑HT3 receptors【6](https://www.michaeljfox.org/grant/evaluation-enteric-nervous-system-pd)】.
• Vagal afferents project to the nucleus tractus solitarius and then to the dorsal motor nucleus of the vagus, modulating the parasympathetic outflow to the gut and, via the locus coeruleus, influencing nigrostriatal dopamine release【1](https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2022.861035/full)】.
• Chronic low‑grade SCFA signaling reduces tyrosine hydroxylase activity in substantia nigra neurons through cAMP‑PKA pathways, lowering extracellular dopamine and preferentially decreasing D1‑mediated direct pathway excitation while sparing D2‑mediated indirect pathway tone【4](https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2021.785666/full)】.
• The resulting D2‑biased striatal state increases beta‑band synchrony between the subthalamic nucleus and globus pallidus externa, a pattern observed in aging basal ganglia networks and predictive of Parkinson’s risk【4】.

Testable Predictions

1. Microbiota manipulation: Transferring feces from aged mice with high SCFA producers to young germ‑free mice will increase fecal SCFA concentrations, elevate vagal afferent firing (measured by electrophysiology), and within 4 weeks reduce striatal dopamine release (via fast‑scan cyclic voltammetry) while increasing D2/D1 receptor binding ratio (PET with [11C]raclopride and [11C]NMSP).
2. Vagal blockade: Subdiaphragmatic vagotomy in aged mice will prevent the SCFA‑induced shift in D1/D2 balance despite elevated luminal SCFA, preserving youth‑like striatal synchrony (LFP coherence) and normal habit learning performance on a sequential lever‑press task.
3. SCFA receptor antagonism: Chronic administration of a GPR41/43 antagonist will rescue dopamine levels and D1/D2 ratio in aged rodents without altering microbiota composition, demonstrating that the receptor‑mediated vagal signal, not the microbes per se, drives the basal ganglia phenotype.
4. Human prodromal cohort: In REM sleep behavior disorder patients (a prodromal Parkinson’s cohort), baseline fecal butyrate levels will negatively correlate with putamen D1 binding potential (positron emission tomography) and positively correlate with resting‑state beta power in the sensorimotor cortex, even after controlling for age and UPDRS scores.

Falsifiability

If any of the above manipulations fail to produce the predicted directional changes—for example, vagotomy does not alter the D1/D2 ratio despite high SCFA, or GPR41/43 blockade does not restore dopamine levels—the hypothesis that gut‑derived SCFAs set striatal D1/D2 tone via vagal afferents would be refuted. Conversely, consistent supportive data would invert the conventional top‑down model, positioning intestinal metabolic output as the primary driver of basal ganglia aging and Parkinson’s risk.

Implications for Intervention

A bottom‑up longevity stack would prioritize: (1) modulation of microbial SCFA production through targeted prebiotics or precision antibiotics; (2) vagal afferent tuning via neuromodulation (e.g., transcutaneous auricular vagal stimulation) to normalize signaling; and (3) downstream dopaminergic support only after gut‑vagal axis normalization, thereby aligning therapeutic timing with the prodromal window when enteric pathology precedes central dopaminergic loss.